García-Silva, SusanaVico-Alonso, CristinaMeyer, LisaEnderle, DanielSanchez, J AquilesOnteniente, María Del MarNoerholm, MikkelSkog, JohanRodríguez-Peralto, José-LuisOrtiz-Romero, Pablo-LuisPeinado Selgas, Hector2023-02-232023-02-232023-02-15J Invest Dermatol. 2023 Feb 15;S0022-202X(23)00091-X.http://hdl.handle.net/20.500.12105/15538This study was approved by the institutional ethical review board (CEIC) of Hospital 12 de Octubre (Madrid, Spain) and institutional review board information is04.625 version September 26th2018 on Act 20/18 dated by November 13th2018. Written informed consent was obtained from all participants. Conflict of Interest StatementJohan Skog has patents for exosome-based technologies and is an employee and shareholder of Bio-techne. J. Aquiles Sanchez is an employee of Bio-techne. Lisa Meyer, Daniel Enderle and Mikkel Noerholm are former employees of Bio-techne. Authors declare no additional conflicts of interesTo the editor, cutaneous melanoma in its early stages is a curable disease by surgery of skin lesions. However, intermediate stages display variable outcomes. BRAF V600 mutations are the most frequent alterations in melanoma ocurring in 35-50% of patients ( Luke et al., 2017) and remain informative for guiding first-line treatment election ( Robert et al., 2019).engAMhttp://creativecommons.org/licenses/by-nc-nd/4.0/BRAFMelanomaBiomarkersOncologyTumors markersCancerAttribution-NonCommercial-NoDerivatives 4.0 Internacional3680440510.1016/j.jid.2023.01.0251523-1747The Journal of investigative dermatologyopen access